# Natural Alternatives International Inc: overview NAII · Nasdaq · CIK 787253 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/naii.md) · [Financials](/companies/naii/financials.md) · [Filings](/companies/naii/filings.md) · [Insiders](/companies/naii/insiders.md) Latest reported revenue: [$34.5m](/filings/0001437749-26-031343.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Sep 28, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001437749-26-031343). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [33.2](/filings/0001437749-25-034473.md) | [34.1](/filings/0001437749-26-004118.md) | [28.8](/filings/0001437749-26-017684.md) | [33.9 d](/filings/0001437749-26-031343.md) | [37.7](/filings/0001437749-25-034473.md) | [34.8](/filings/0001437749-26-004118.md) | [35.5](/filings/0001437749-26-017684.md) | [34.5 d](/filings/0001437749-26-031343.md) | | Gross margin | % | [6.8%](/filings/0001437749-25-034473.md) | [4.9%](/filings/0001437749-26-004118.md) | [6.3%](/filings/0001437749-26-017684.md) | [10.4% d](/filings/0001437749-26-031343.md) | [11.7%](/filings/0001437749-25-034473.md) | [7.2%](/filings/0001437749-26-004118.md) | [1.1%](/filings/0001437749-26-017684.md) | [5.0% d](/filings/0001437749-26-031343.md) | | Operating margin | % | [(5.5%)](/filings/0001437749-25-034473.md) | [(8.2%)](/filings/0001437749-26-004118.md) | [(7.3%)](/filings/0001437749-26-017684.md) | [(5.7%) d](/filings/0001437749-26-031343.md) | [0.8%](/filings/0001437749-25-034473.md) | [(5.3%)](/filings/0001437749-26-004118.md) | [(11.3%)](/filings/0001437749-26-017684.md) | [(38.2%) d](/filings/0001437749-26-031343.md) | | Net margin | % | [(6.0%)](/filings/0001437749-25-034473.md) | [(6.4%)](/filings/0001437749-26-004118.md) | [(7.6%)](/filings/0001437749-26-017684.md) | [(21.3%) d](/filings/0001437749-26-031343.md) | [(0.8%)](/filings/0001437749-25-034473.md) | [(7.3%)](/filings/0001437749-26-004118.md) | [(12.1%)](/filings/0001437749-26-017684.md) | [(39.2%) d](/filings/0001437749-26-031343.md) | | Diluted EPS | $ per share | [(0.33)](/filings/0001437749-25-034473.md) | [(0.37)](/filings/0001437749-26-004118.md) | [(0.37)](/filings/0001437749-26-017684.md) | not reported | [(0.05)](/filings/0001437749-25-034473.md) | [(0.42)](/filings/0001437749-26-004118.md) | [(0.72)](/filings/0001437749-26-017684.md) | not reported | | Free cash flow | $m | [(3.7)](/filings/0001437749-25-034473.md) | [(1.0) d](/filings/0001437749-26-004118.md) | [5.2 d](/filings/0001437749-26-017684.md) | [1.9 d](/filings/0001437749-26-031343.md) | [(5.1)](/filings/0001437749-25-034473.md) | [(7.3) d](/filings/0001437749-26-004118.md) | [1.4 d](/filings/0001437749-26-017684.md) | [(1.7) d](/filings/0001437749-26-031343.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [171](/filings/0001437749-23-026521.md) | [154](/filings/0001437749-24-030208.md) | [114](/filings/0001437749-25-029731.md) | [130](/filings/0001437749-26-031343.md) | [143](/filings/0001437749-26-031343.md) | | Gross margin | % | [17.8%](/filings/0001437749-23-026521.md) | [11.8%](/filings/0001437749-24-030208.md) | [6.0%](/filings/0001437749-25-029731.md) | [7.2%](/filings/0001437749-26-031343.md) | [6.3%](/filings/0001437749-26-031343.md) | | Operating margin | % | [8.0%](/filings/0001437749-23-026521.md) | [3.1%](/filings/0001437749-24-030208.md) | [(7.5%)](/filings/0001437749-25-029731.md) | [(6.7%)](/filings/0001437749-26-031343.md) | [(13.2%)](/filings/0001437749-26-031343.md) | | Net margin | % | [6.3%](/filings/0001437749-23-026521.md) | [1.6%](/filings/0001437749-24-030208.md) | [(6.3%)](/filings/0001437749-25-029731.md) | [(10.5%)](/filings/0001437749-26-031343.md) | [(14.5%)](/filings/0001437749-26-031343.md) | | Diluted EPS | $ per share | [1.74](/filings/0001437749-23-026521.md) | [0.43](/filings/0001437749-24-030208.md) | [(1.23)](/filings/0001437749-25-029731.md) | [(2.28)](/filings/0001437749-26-031343.md) | [(3.43)](/filings/0001437749-26-031343.md) | | Free cash flow | $m | [(14.6)](/filings/0001437749-23-026521.md) | [(6.5)](/filings/0001437749-24-030208.md) | [(4.5)](/filings/0001437749-25-029731.md) | [2.3](/filings/0001437749-26-031343.md) | [(12.6)](/filings/0001437749-26-031343.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/naii/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CALDWELL SUTTER CAPITAL, INC.](/funds/702007.md) | 2026-06-30 | $1.2m | 498,220 | | Reduced −572 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $802.5k | 335,789 | | Reduced −18,950 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $735.2k | 307,630 | | Added +39,380 | | [Mink Brook Asset Management LLC](/funds/2052205.md) | 2026-06-30 | $701.3k | 293,447 | | Reduced −262 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $663.1k | 277,457 | | Reduced −13,899 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $504.0k | 210,880 | | Unchanged | | [Integrated Wealth Concepts LLC](/funds/1737109.md) | 2026-06-30 | $210.8k | 88,186 | | Added +76,186 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $181.0k | 75,746 | | Added +32,038 | | [BRIDGEWAY CAPITAL MANAGEMENT, LLC](/funds/1107261.md) | 2026-06-30 | $147.0k | 61,495 | | Reduced −13,821 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $104.5k | 43,711 | | Reduced −8,694 | ## Recent filings [All 478 filings](/companies/naii/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-23 | 16:11 ET | [DEF 14A](/filings/0001437749-26-033415.md) | Proxy statement, period 2026-12-11 | 0001437749-26-033415 | | 2026-09-28 | 16:16 ET | [10-K](/filings/0001437749-26-031343.md) | Annual report, period 2026-06-30 | 0001437749-26-031343 | | 2026-05-19 | 06:03 ET | [10-Q](/filings/0001437749-26-017684.md) | Quarterly report, period 2026-03-31 | 0001437749-26-017684 | | 2026-05-01 | 17:00 ET | [8-K](/filings/0001437749-26-014497.md) | 5.02 Departure or appointment of officers or directors | 0001437749-26-014497 | | 2026-03-20 | 16:30 ET | [8-K](/filings/0001437749-26-009247.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001437749-26-009247 | | 2026-02-13 | 16:17 ET | [10-Q](/filings/0001437749-26-004118.md) | Quarterly report, period 2025-12-31 | 0001437749-26-004118 | | 2025-12-17 | 17:13 ET | [8-K](/filings/0001437749-25-038181.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001437749-25-038181 | | 2025-12-12 | 20:10 ET | [8-K](/filings/0001437749-25-037601.md) | 5.07 Shareholder vote results | 0001437749-25-037601 | | 2025-11-12 | 16:35 ET | [10-Q](/filings/0001437749-25-034473.md) | Quarterly report, period 2025-09-30 | 0001437749-25-034473 | | 2025-10-23 | 16:16 ET | [DEF 14A](/filings/0001437749-25-031627.md) | Proxy statement, period 2025-12-05 | 0001437749-25-031627 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001437749-26-031343.md), filed Sep 28, 2026. ## Forecast league Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c87bc192-4638-4bce-a9b1-c079bf23d958) ## About the filer - CIK: 787253 - Tickers: NAII - Exchange: Nasdaq - SIC code: 2833 Medicinal Chemicals & Botanical Products - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:24 ET. No prices; not investment advice.